Core Viewpoint - Pacira BioSciences has settled litigation with Fresenius Kabi and others regarding patents for EXPAREL, allowing Fresenius to sell a volume-limited amount of generic bupivacaine liposome injectable suspension starting in early 2030, with unlimited sales permitted from 2039 [1][3][4]. Group 1: Settlement Details - The settlement includes Consent Judgments that prevent Fresenius from marketing the generic product before the expiration of the relevant patents, except as specified in the settlement [2]. - Fresenius will receive a license to manufacture and sell a limited volume of the generic product starting in early 2030, with the last of Pacira's patents expiring on July 2, 2044 [3]. - The volume-limited sales will start at a high-single-digit percentage of total U.S. market volumes, increasing to the low thirties by 2033, and reaching a maximum in the high thirties for the final three years of the agreement [4]. Group 2: Company Strategy and Products - Pacira emphasizes confidence in its intellectual property portfolio and aims to focus on advancing its 5x30 strategy to enhance its leadership in musculoskeletal pain management [5]. - The company offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, and is developing PCRX-201, a gene therapy for osteoarthritis [6].

Core Viewpoint - Pacira BioSciences has initiated the Phase 2 ASCEND study for PCRX-201, a novel gene therapy aimed at treating knee osteoarthritis by enhancing the production of the anti-inflammatory protein IL-1Ra [1][2][8] Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with a commitment to transforming patient lives [1][10] - The company has three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera° [10] Study Design - The ASCEND study is a two-part, multicenter trial involving approximately 135 patients aged 45 to 80 with painful knee osteoarthritis [3][5] - Patients will be randomized into treatment groups receiving either PCRX-201 or saline, with two different doses being evaluated [4][6] Drug Details - PCRX-201 is based on a proprietary high-capacity adenovirus vector platform, designed for local administration to target chronic inflammation in knee osteoarthritis [7][12] - The therapy aims to provide sustained pain relief and improve function, with previous Phase 1 results showing effects lasting up to two years [2][8] Regulatory Designations - PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Advanced Therapy Medicinal Products (ATMP) designation from the EMA, indicating its potential to address significant unmet medical needs [8] Manufacturing and Scalability - The drug product for Part B of the study will utilize a newly developed suspension-based batch manufacturing process, aimed at commercial scale-up [5] - The high-capacity adenovirus vector platform allows for efficient gene delivery and the potential for cost-effective production of therapies [12]

SASKATOON, Saskatchewan, April 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a definitive share purchase agreement with an arm’s length vendor (the “Vendor”) dated April 1, 2025 to acquire a 100% interest in a pre-1954 charter company (the “Charter Company”) in Ontario, Canada (the “Acquisition”). The Corporation has agreed to purchase the Charter Company for $2,090,000, which will be paid using cash on hand ( ...

CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long- acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic ...

Shares of Pacira BioSciences (PCRX) have surged 66.8% in the past six months against the industry’s decline of 8.7%.  The stock has also outperformed the sector and the S&P 500 index during this timeframe.Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.PCRX Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchExparel’s Performance Fuels PCRX GrowthExparel, Pacira’s flagship pain-management pro ...

Group 1 - The article discusses the challenges faced by Pacira BioSciences, Inc. (NASDAQ: PCRX) that have negatively impacted its share price [2] - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [2] - The author, Edmund Ingham, has extensive experience in biotech consulting and has prepared detailed reports on over 1,000 companies in the sector [2] Group 2 - The article indicates that the author may initiate a long position in PCRX within the next 72 hours, suggesting potential interest in the stock [3] - There is a disclaimer stating that past performance does not guarantee future results, emphasizing the speculative nature of investments in the biotech sector [4]

-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders. Pacira issued the follo ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsu ...

Yes, the market has certainly seen its share of volatility recently. It’s led to some treacherous slides in equity prices. It seems that the high beta names are really getting slapped down. In most cases, the mega caps have stood in relatively well. Tuesday’s move to the 200-day on the S&P 500 brought out the bargain shoppers too. Many stocks managed to push into positive territory.On a bounce from those lows, resist the urge to buy everything that moves. Rather, look for stocks with strong earnings trends ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline.So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to d ...